Does Insurance Cover GLP-1 for Weight Loss in 2026?

Whether insurance covers a GLP-1 drug like Wegovy or Zepbound for weight loss depends almost entirely on your specific plan, not on the drug itself. Many large commercial insurers, including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare, list these medications on the formularies of at least some plans, but coverage is never automatic and usually requires prior authorization.

The biggest dividing line is whether your plan is fully insured or self-funded. About 60% of commercial members are in self-funded employer plans, where the employer, not the insurer, decides what is covered and can exclude anti-obesity medications entirely regardless of the insurer's standard formulary. That is why two coworkers' neighbors with the same insurance card can get completely different answers. A second key distinction is the diagnosis: GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro) are far more widely covered than the same molecules prescribed for weight loss (Wegovy, Zepbound), even though they overlap. The only way to know your coverage for certain is to call the member services number on your insurance card and ask specifically whether anti-obesity medications, and the exact drug your doctor recommends, are covered under your plan. Bring the drug name and your doctor's diagnosis code when you call.

Starting July 1, 2026, the Medicare GLP-1 Bridge program gives eligible Part D members access to weight-loss GLP-1 medications, the first time Medicare has covered these drugs for obesity rather than only for diabetes or heart disease. Under the program, eligible members can get Wegovy or Zepbound for a $50 copay per 30-day supply.

This is a meaningful shift because Medicare has historically been barred from covering drugs used solely for weight loss. Eligibility is based on a BMI of 35 or higher, or 27 or higher with other clinical criteria, according to the program details. A few caveats matter: the $50 copay does not count toward the Part D annual out-of-pocket cap, and the Bridge is temporary, designed to run through the end of 2027 until a follow-on model (called BALANCE) is scheduled to begin. If you or a family member is on Medicare, this is worth raising with your prescriber and checking against your specific Part D plan, since participation and exact terms can vary. The program signals a broader trend: as long-term data on GLP-1s and heart health accumulates, payers are slowly expanding access. Always confirm current details with Medicare directly, since program rules can change.

Even when your plan covers a GLP-1, you can still face a high monthly cost because these drugs usually sit on a specialty or high tier of your formulary. Insurance plans sort drugs into tiers, and the higher the tier, the larger your share of the cost. Wegovy and Zepbound commonly land on Tier 4 specialty, where copays or coinsurance can leave you paying $200 to $300 a month even with active coverage.

There are a few reasons for this. The list price of these medications is roughly $1,000 to $1,350 a month before any discounts, so even a modest coinsurance percentage adds up. Plans also use tiering to steer members toward lower-cost options first. On top of tiering, many plans add a prior authorization requirement and sometimes step therapy, meaning you must try and fail a cheaper approach before the GLP-1 is approved. If your out-of-pocket cost feels surprisingly high despite being covered, ask your pharmacist or insurer exactly which tier the drug is on and whether a different covered GLP-1 sits on a lower tier. Sometimes switching between Wegovy and Zepbound, or using a manufacturer savings card, dramatically changes what you actually pay at the counter.

Yes. Manufacturer savings cards are the single most effective tool for lowering GLP-1 costs, and for commercially insured patients who qualify they can cut copays to as little as $0 per month. Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both run savings programs for people with private insurance, though they exclude government plans like Medicare and Medicaid.

If you have commercial insurance that covers the drug, a savings card typically caps your monthly cost at a set low amount for a defined period. If your insurance does not cover the drug, the same manufacturers offer self-pay options: Eli Lilly's direct-purchase vials and Novo Nordisk's self-pay channels have brought cash prices down compared with the full list price, often into the few-hundred-dollars-a-month range. Other levers include FSA and HSA accounts, which let you pay with pre-tax dollars, and telehealth providers that bundle prescribing with lower-cost sourcing. Compounded versions exist but became more restricted after the FDA declared the shortage resolved, so approach them cautiously and verify the pharmacy's legitimacy. The practical move is to stack what you qualify for: confirm coverage, apply a savings card if commercially insured, and use FSA/HSA dollars for whatever remains. For a deeper breakdown of every discount, see our full guide to GLP-1 savings cards.

To get a GLP-1 approved for weight loss, you and your doctor usually need to satisfy a prior authorization by documenting that you meet clinical criteria. The most common requirements are a qualifying BMI (typically 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, sleep apnea, or prediabetes) and evidence that you have tried lifestyle changes such as diet and exercise.

To improve your odds, ask your prescriber to document your BMI, any related health conditions, and your history of weight-management efforts directly in the prior authorization. If you are denied, do not stop there: denials are frequently overturned on appeal. Request the specific reason for denial in writing, have your doctor submit a letter of medical necessity, and if needed file a formal appeal, which insurers are legally required to review. Persistence pays off because the criteria are often met on a second, better-documented submission. It also helps to ask whether your plan prefers a particular GLP-1, since prescribing the plan's preferred drug can speed approval. Throughout the process, keep a simple log of dates, names, and reference numbers from every call. The administrative side is genuinely the hardest part of GLP-1 treatment for many people, but a well-documented request and a willingness to appeal are what separate approval from denial.